Zykadia (ceritinib) / Novartis, BeiGene  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
NCT01828112 / 2012-005637-36: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Completed
3
231
Europe, Canada, Japan, US, RoW
Ceritinib, pemetrexed, docetaxel
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
01/16
11/23
ASCEND-4, NCT01828099 / 2013-000319-26: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Checkmark ASCEND-4 trial in ALK+ NSCLC
Apr 2017 - Apr 2017: ASCEND-4 trial in ALK+ NSCLC
Checkmark ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Sep 2016 - Sep 2016: ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Completed
3
376
Europe, Japan, RoW
Ceritinib, LDK378, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/16
01/24
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25

Download Options